BEAM THERAPEUTICS DL-,01

An arbitration panel ruled in a dispute with Prime Medicine that the development rights for the experimental gene therapy PM647 fall within Prime Medicine’s licensed field, causing Beam Therapeutics to lose those rights. This also affects the competing AATD program BEAM-302 and increases competitive and patent-related uncertainty for Beam. The stock fell from its 52-week high and gave back gains, further pressured by a risk-averse market environment after geopolitical tensions that hit high-growth biotech stocks disproportionately. » More on de.investing.com

Beam Therapeutics still plans to submit the approval application for BEAM-101 to treat severe sickle cell disease in 2026. BEAM-302 is pursuing an accelerated FDA approval for alpha-1 antitrypsin deficiency, and an IND has been submitted for BEAM-304 to treat phenylketonuria. The company expects noticeable revenue growth from 2028 and holds about $1.2 billion in cash, which should secure funding through 2029. » More on finanzen.net

Beam Therapeutics’ stock climbed to a 52-week high of $36.89 and is currently trading at $37.02 with a market capitalization of $3.63 billion. InvestingPro rates the stock as potentially overvalued versus its fair-value estimate; investors should note the high volatility, with a beta of 2.18. The FDA approved the IND application for BEAM-304 to treat phenylketonuria, Beam presented Phase 1/2 data for BEAM-302, and H.C. Wainwright confirmed a buy recommendation with an $80.00 price target; updated data on Risto-Cel will be presented at the EHA. » More on de.investing.com